Leishmaniasis pp 807-817 | Cite as

Site Specific Antileishmanial Drug Delivery

  • David Hart
  • Jayne Lawrence
Part of the NATO ASI Series book series (NSSA, volume 171)


Over the past decade progress has been made towards the rational development of drug delivery vesicles for the treatment of visceral leishmaniasis. After intravenous (IV) administration, foreign colloidal particles, such as phospholipid vesicles (liposomes) and nanoparticles, are rapidly cleared by the macrophages of the reticuloendothelial system (RES) — particularly those residing in the liver and spleen. While this natural distribution may cause serious limitations for the use of colloidal carriers in the treatment of a number of diseases, including solid tumours or metastases and cutaneous leishmaniasis, it offers considerable advantages in the treatment of visceral leishmaniasis.


Visceral Leishmaniasis Cutaneous Leishmaniasis Antileishmanial Activity Leishmania Donovani Sodium Stibogluconate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Dutz, W., Agarval, N., Bashardost, M.Z., Bently, G. & Kindmark, C.O., (1987) Topical Therapy of Cutaneous Leishmaniasis with 2% Ketokonazole Oitment and DMSO Int. J. Dermatology 26, 199Google Scholar
  2. El-On, J., Jacobs, G.J., Witztum, E, and Greenblatt, C.L (1984) Development of Topical Treatment for Cutaneous Leishmaniasis Caused by Leishmania major in Experimental Animals. Antimicrobial Agents and Chemotherapy 26, 745–751PubMedCrossRefGoogle Scholar
  3. Hart, D.T., Vickerman, K & Coombs, G.H. (1981) The in vitro transformation of Leishmania mexicana mexicana amastigotes to promastigotes: Nutritional requirements and effect of drugs. Parasitology 83, 529–541.CrossRefGoogle Scholar
  4. Hart, D.T. & Coombs, G.H. (1982) Leishmania mexicana : Energy metabolism of amastigotes and promastigotes. Exptl. Parasitol. 54, 397–409.CrossRefGoogle Scholar
  5. Hart, D.T. & Opperdoes, F.R. (1984) The occurrence of glycosomes (microbodies) in the promastigote stage of four major Leishmania species. Mol. Biochem. Parasitol. 13, 159–172.PubMedCrossRefGoogle Scholar
  6. Hart, D.T. (1987) Leishmania host-parasite interactions: The development of chemotherapeutic targets and specific drug delivery systems. I. Lipoprotein-mediated antileishmanial chemotherapy. In: Host-Parasite Cellular and Molecular Interactions in Protozoal Infections, eds K-P. Chang & D. Snary, Springer-Verlag, Berlin.Google Scholar
  7. New, R.R.C., Chance, M.L. & Heath, S. (1981) The Treatment of Experimental Cutaneous Leishmaniasis with Liposome-entrapped. Pentostam Parasitology 83, 519–527CrossRefGoogle Scholar
  8. New, R.R.C., Chance, M.L. and Heath, S. (1983) Liposome Therapy For Experimental Cutaneous and Visceral Leishmaniasis. Biol. Cell 47, 59–64Google Scholar
  9. Panosain, C.B., Barza, M., Szoka, F. & Wyler, D.J. (1984) Treatment of Experimental Cutaneous Leishmaniasis with Liposome-intercelated Amphotericin B Antimicrobial Agents and Chemotherapy 25, 655–656CrossRefGoogle Scholar
  10. Van Berkel T.J.C., Kruijt J.K., Harkes L., Nagelkerke J.F., Spanjer H. & Kempen H-J. (1986) In: Site-specific Drug Delivery. Eds Tomlinson and Davis. John Wiley & Sons Ltd. London.Google Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • David Hart
    • 1
  • Jayne Lawrence
    • 1
  1. 1.Drug Delivery Special Interest Group Departments of Biology and PharmacyKing’s College London (KQC)LondonUSA

Personalised recommendations